Fusion Pharmaceuticals Inc. (FUSN)
NASDAQ: FUSN · IEX Real-Time Price · USD
21.43
+0.03 (0.14%)
At close: Apr 30, 2024, 4:00 PM
21.47
+0.04 (0.18%)
After-hours: Apr 30, 2024, 4:57 PM EDT
Fusion Pharmaceuticals Revenue
In the year 2023, Fusion Pharmaceuticals had annual revenue of $2.07M with 41.55% growth.
Revenue (ttm)
$2.07M
Revenue Growth
+41.55%
P/S Ratio
879.43
Revenue / Employee
$20,475
Employees
101
Market Cap
1.82B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.07M | 607.00K | 41.55% |
Dec 31, 2022 | 1.46M | 21.00K | 1.46% |
Dec 31, 2021 | 1.44M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
BrightSpring Health Services | 8.83B |
Amneal Pharmaceuticals | 2.39B |
NeoGenomics | 591.64M |
Galapagos NV | 266.36M |
Twist Bioscience | 262.36M |
Ginkgo Bioworks Holdings | 251.46M |
Recursion Pharmaceuticals | 44.58M |
FUSN News
- 5 days ago - Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order - PRNewsWire
- 21 days ago - Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 - PRNewsWire
- 5 weeks ago - INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN - PRNewsWire
- 5 weeks ago - Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates - PRNewsWire
- 6 weeks ago - FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN - Business Wire
- 6 weeks ago - FUSN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Fusion Pharmaceuticals Inc. Is Fair to Shareholders - Business Wire
- 6 weeks ago - AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion - Market Watch
- 6 weeks ago - AstraZeneca to buy Fusion Pharma for $2 billion in cash - Reuters